Bavarian Nordic Deal Opens Up Potential China Market For RSV Vaccine

Company Lags Behind Big Players, But Could Seize Asian Opportunity

As three big players get set to reveal pivotal data for adult RSV vaccines, Bavarian Nordic seals a deal for its candidate that could still claim a sizeable niche if a late-stage trial delivers.

Bavarian Nordic
Bavarian Nordic 's RSV vaccine is about to begin its Phase III trials, which could mean a launch as soon as 2024 • Source: Alamy

Bavarian Nordic has sealed a deal with Shanghai-based Nuance Pharma to develop and market its respiratory syncytial virus (RSV) vaccine candidate across China and numerous Southeast Asian territories, if it gains approval.

The deal sees Bavarian Nordic receive an upfront payment of $12.5m and makes it eligible for future milestone payments of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.